Tumor-Agnostic Therapies and the Future of HER2 in Oncology

Labcorp, Rebecca Previs, Heidi Ko, HER2, NGS, precision oncology, tumor agnostic, breast cancer, gastric cancer, biomarker, ERBB2, IHC, FISH, biomarker

What tumor-agnostic approvals mean for HER2, NGS, and precision oncology — and how they’re changing treatment across cancer types.

Jun 8^th • 20 mins listen

Patient Education for Next-Generation Sequencing to Guide Cancer Therapy

Highlights From Today’s Episode “With next-generation sequencing (NGS), multiple biomarkers can be evaluated using one test. So, in cancer care, we’re learning that any given tumor may harbor a variety of variants. So, if we’re considering using in situ hybridization (ISH)…

Mar 30^th • 47 mins listen